Treatment of experimental mesangioproliferative glomerulonephritis with non-anticoagulant heparin: Therapeutic efficacy and safety

Laboratory Investigation

Volumn 76, Issue 4, 1997, Pages 505-516

  Burg, Michael ^a   Ostendorf, Tammo ^a   Mooney, Andrew ^b   Koch, Karl Martin ^a   Floege, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Division of Nephrology 6840 Medizinische Hochschule ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; DESMIN; HEPARIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GLOMERULONEPHRITIS; HEPARINIZATION; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030962491     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Adler S (1988). Inhibition of rat glomerular visceral epithelial cell growth by heparin. Am J Physiol 255:F781-F786.
2. Alpers CE, Hudkins KL, Gown AM, and Johnson RJ (1992). Enhanced expression of 'muscle-specific' actin in glomerulonephritis. Kidney Int 41:1134-1142.
3. Altmannsberger M, Weber K, Droste R, and Osborn M (1985). Desmin as a specific marker for rhabdomyosarcomas of human and rat origin. Am J Pathol 118:85-95.
4. Bagchus WM, Hoedemaeker PJ, Rozing J, and Bakker WW (1986). Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. Lab Invest 55:680-687.
5. Bagchus WM, Jeunink MF, Rozing J, and Elema JD (1989). A monoclonal antibody against rat platelets: Tissue distribution in vitro and in vivo. Clin Exp Immunol 75:317-323.
6. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, and Savill J (1994). Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 94:2105-2116.
7. Ballermann BJ (1989). Regulation of bovine glomerular endothelial cell growth in vitro. Am J Physiol 256:C182-C189.
8. Castellot JJ, Hoover RL, Harper PA, and Karnovsky ML (1985). Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial cell proliferation. Am J Pathol 120:427-435.
9. Castellot JJ, Hoover RL, and Karnovsky ML (1986). Glomerular endothelial cells secrete a heparinlike inhibitor and a peptide stimulator of mesangial cell proliferation. Am J Pathol 125:493-500.
10. Castellot JJ, Pukac LA, Caleb BL, Wright TC, and Karnovsky ML (1989). Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells. J Cell Biol 109:3147-3152.
11. Coffey AK and Karnovsky MJ (1985). Heparin inhibits mesangial cell proliferation in Habu-venom-induced glomerular injury. Am J Pathol 120:248-255.
12. Couser WG and Stilmant MM (1975). Mesangial lesions and focal glomerular sclerosis in the aging rat. Lab Invest 33:491-501.
13. D'Amico G (1987). The commonest glomerulonephritis in the world: IgA nephropathy. QJM 245:709-727.
14. Dijkstra CD, Dopp EA, Joling P, and Kraal G (1985). The heterogeneity of mononuclear phagocytes in lympoid organs: Distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 54:589-599.
15. Eitner F, Westerhuis R, Burg M, Rüther U, Gröne HF, Ostendorf T, Koch KM, Rees AJ, and Floege J (1997). On the role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int 51:69-78.
16. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, and Johnson RJ (1992a). Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41:297-309.
17. Floege J, Eng E, Young BA, Couser WG, and Johnson RJ (1993). Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 43:369-380.
18. Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, and Couser WG (1991a). Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 40:477-488.
19. Floege J, Johnson RJ, Gordon K, Yoshimura A, Campbell C, Iruela Arispe L, Alpers CE, and Couser WG (1992b). Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney Int 42:573-585.
20. Floege J, Topley N, Hoppe J, Barrett TB, and Resch K (1991b). Mitogenic effect of platelet-derived growth factor in human glomerular mesangial cells: Modulation and/or suppression by inflammatory cytokines. Clin Exp Immunol 86: 334-341.
21. Gospodarowicz D and Cheng J (1986). Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128: 475-484.
22. Hugo C, Hugo C, Pichler R, Gordon K, Schmidt R, Amieva M, Couser WG, Furthmayr H, and Johnson RJ (1996). The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. J Clin Invest 97:2499-2508.
23. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, Couser WG, Alpers CE, and Johnson RJ (1995). Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 147:1715-1727.
24. Johnson RJ, Garcia RL, Pritzl P, and Alpers CE (1990). Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti-mesangial cell antibodies in the rat. Am J Pathol 136:369-374.
25. Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzl P, Gordon K, and Gown AM (1991). Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis: Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 87:847-858.
26. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, and Floege J (1996). Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49:666-678.
27. Limanni A, Fleming T, Molina R, Hufnagel H, Cunningham RE, Cruess DF, and Sharefkin JB (1988). Expression of genes for platelet-derived growth factor in adult human venous endothelium. A possible non-platelet-dependent cause of intimal hyperplasia in vein grafts and perianastomotic areas of vascular prostheses. J Vasc Surg 7:10-20.
28. Morita T and Churg J (1983). Mesangiolysis. Kidney Int 24:1-9.
29. Pukac LA, Hirsch GM, Lormeau JC, Petitou M, Choay J, and Karnovsky MJ (1991). Antiproliferative effects of novel, non-anticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivo. Am J Pathol 139:1501-1509.
30. Purkerson ML, Tollefsen DM, and Klahr S (1988). N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 81:69-74.
31. Reilly CF, Kindy MS, Brown KE, Rosenberg RD, and Sonenshein GE (1989). Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem 264:6990-6995.
32. Saito Y, Kida H, Takeda SI, Yoshimura M, Yokoyama H, Koshino Y, and Hattori N (1988). Mesangiolysis in diabetic glomeruli: Its role in the formation of nodular lesions. Kidney Int 34:389-396.
33. Shin W, Hines WH, and Neilson EG (1988). Effects of cyclosporin A on the development of immune-mediated interstitial nephritis. Kidney Int 33:1113-1118.
34. Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, and Yamanaka N (1995). Apoptosis in the repair process of experimental proliferative glomerulonephritis. Kidney Int 47: 114-121.
35. Skalli O, Ropraz P, Treciak K, Benzonana G, Gillesen D, and Gabbiani G (1986). A monoclonal antibody against alpha-smooth muscle actin: A new probe for smooth muscle differentiation. J Cell Biol 103:2787-2796.
36. Slomowitz LA, Klahr S, Schreiner G, and Ichikawa I (1988). Progression of renal diseases. N Engl J Med 319:1547-1548.
37. Spickett GP, Brandon MR, Mason DW, Williams AF, and Woollett GR (1983). MRC OX-22, a monoclonal antibody that labels a new subset of T-lymphocytes and reacts with the high molecular weight form of the leucocyte-common antigen. J Exp Med 158:795-810.
38. Striker LJ, Peten EP, Elliot SJ, Doi T, and Striker GE (1991). Mesangial cell turnover: Effect of heparin and peptide growth factors. Lab Invest 64:446-456.
39. Tang WW and Wilson CB (1992). Heparin decreases mesangial matrix accumulation after selective antibody-induced mesangial cell injury. J Am Soc Nephrol 3:921-929.
40. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, and Fuks Z (1991). Extracellular sequestration and release of fibroblast growth factor: A regulatory mechanism? Trends Biochem Sci 16:268-271.
41. Wang A and Templeton DM (1996). Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates. Kidney Int 49:437-448.
42. Yamamoto T and Wilson CB (1987). Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int 32:514-525.